Background
==========

It was recently hypothesized that the lentiviral reservoir in central memory (T~CM~) and transitional memory (T~TM~) CD4+ cells could be restricted by new therapies targeting pathways downstream of homeostatic proliferation or pathways associated with "stem cell--ness", such as those developed for the treatment of leukemias. Gar1041 is one such epigenetic drug adopted in the experimental treatment of certain types of leukemia.

Methods
=======

SIVmac251-infected primates with viral loads stably suppressed by ART (tenofovir/emtricitabine/raltegravir) were administered for two months: Gar1041 twice daily (a starting dose of 1.5g in the first week followed by 2g in the remaining period). ART was continued during Gar1041 treatment. Proviral DNA was quantitated using a Taqman real-time PCR.

Results
=======

The proviral DNA content of PBMCs, which had shown no significant changes during 54 days of treatment with ART alone (p \>0.05), fell below the level of detection (2 copies/10^6^ cells) in all study subjects within one month of Gar1041 treatment (p \<0.05; Bonferroni's test following significant \[p=0.0003\] repeated measures ANOVA). No significant changes were noticed in a control group treated with ART alone (p=0.49). The decrease in proviral DNA was associated with a significant (p=0.0156) decrease in the proportions of the T~CM~ CD4+ cell subpopulation in peripheral blood. However, both proviral DNA and the proportions of T~CM~ CD4+ rebound after two months of therapy.

Conclusions
===========

The present study furnishes proof of concept that pharmacological strategies may impact on the proviral DNA reservoir. However, the renewal of the phenotype T~CM~ compartment, associated with the reconstitution of proviral DNA in peripheral blood from an as yet unidentified reservoir, will require integration with other experimental approaches.
